Stately Bio

At ISCT last week, we gathered for an intimate dinner with David DiGiusto and a star-studded list of industry leaders to discuss AI in cell therapy manufacturing: Isabelle Rivière, Xiaokui Zhang, PhD, Hideto Yamaguchi, Deborah Hursh, Chris Bartley, Lynne Frick, Kévin Alessandri, Christian Elabd, Scott Burger. It was a wonderful and inspiring conversation -- thanks to everyone for sharing your stories and your wisdom.

We are honored to receive the Top Scoring Start-Up (Enabler) Abstract Award and will be presenting two oral abstracts at ISCT, International Society for Cell & Gene Therapy 2025 later this week. Come join us in New Orleans to learn more about our work! May 8, 3:45 - 4:45 pm: Label-free, single-cell quantification of granulocyte macrophage progenitors from brightfield imaging May 9, 8:00 - 9:00 am: Machine learning-driven optimization of hepatocyte functional maturation from hPSC

After 3 years in stealth, I'm excited to officially unveil Stately Bio. During that time, our small but mighty team has been laser-focused on one mission: developing the next generation of life-saving regenerative medicines with the world's most advanced ML cell imaging platform. Until now, our understanding of cells has been limited by technologies that require breaking open, destroying, or modifying cells in order to study them. Not good for cell therapy, where cells need to be alive! At Stately, we pair the latest in computer vision and machine learning to identify and monitor cells using only label-free, live-cell compatible imaging, with no need for fluorescent tags or stains. Using our tech to improve stem cell differentiation protocols, we've developed an in-house liver program that outperforms previous protocols by 3-10x on key, clinically-relevant function assays. We've also partnered with several pharma and industry groups, including with the New York Blood Center to identify specific subpopulations of stem cell-derived immune cells faster and more efficiently than currently possible. We will be showcasing this work as well as our in-house program next week at the ISCT, International Society for Cell & Gene Therapy 2025 Scientific Annual Meeting in New Orleans. Today we're also announcing $12M in seed funding led by AIX Ventures, with participation from Dimension, Foothill Ventures, Village Global, Caffeinated Capital, Mitsui & Co. Global Investment, Inc., BoxOne Ventures, Axial, Jeff Dean, Jeremy Wertheimer, and Tom Berry. I had the pleasure to speak with Andrew Dunn at Endpoints News who shares the news: https://xmrrwallet.com/cmx.plnkd.in/gTDWTRb5